{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-286825","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2026-06-29T11:15:14+00:00","discovered_at":"2026-06-29T11:20:00.280544+00:00","generated_at":"2026-06-29T11:20:14.178513+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"REGENXBIO doses first patient in Phase IIb/III DR trial; earns $100M milestone from AbbVie","bullets":["First patient dosed in Phase IIb/III NAAVIGATE trial of sura-vec for diabetic retinopathy using suprachoroidal delivery.","Triggered $100M milestone payment from AbbVie, expected in July 2026.","Phase IIb portion to enroll ~135 patients in U.S.; primary endpoint is ≥2-step DRSS improvement at one year.","To present 2.5-year ALTITUDE and 5-year subretinal data at ASRS July 2026.","Topline data from ATMOSPHERE and ASCENT pivotal trials expected Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-286825","json":"https://secwatch.observer/filing/0001193125-26-286825.json","markdown":"https://secwatch.observer/filing/0001193125-26-286825.md","text":"https://secwatch.observer/filing/0001193125-26-286825.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526286825/0001193125-26-286825-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526286825/rgnx-20260623.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T11:20:14.178513+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}